Search results

According to data from DSM Group, the pharmaceutical market volume at distributor prices reached 2.87 trillion rubles in 2025, representing a 19% increase compared to 2024. The main driver of growth was the public sector, which expanded by 26% year-on-year, largely due to increased deliveries to healthcare institutions under contracts signed at the end of…

The strategy for developing the bioeconomy sector предусматривает создание новых рынков, включая синтетическую биологию, промышленную микробиологию, биополимеры, биотопливо и продукты питания нового поколения, сообщил глава Минпромторга Антон Алиханов. Russia plans to reduce its dependence on imports of critical biotechnological components—such as enzymes, starter cultures, and certain types of protein products—by at least half by 2030.…

By 2030, Russia plans to build at least 10 new pharmaceutical manufacturing facilities, Russian Minister of Industry and Trade Anton Alikhanov said at a meeting between President Vladimir Putin and members of the government. “The industrial base of the sector has largely been formed. By 2030, it is planned to build at least 10 additional…

The share of domestically produced medicines in Russia stands at 63%, and exceeds 80% in government procurement, Russian Minister of Industry and Trade Anton Alikhanov reported at a meeting attended by Russian President Vladimir Putin devoted to the results of the December “Direct Line.” “The expansion of production capacity has enabled us to reach a…

The special procedure for the sale in Russia of registered foreign medicinal products will remain in effect until December 31, 2027, according to the government’s press service. The measure concerns the possibility of selling foreign medicines in their original foreign packaging. “At the same time, the label must be in Russian,” the statement says. The…

Russian scientists have developed a drug for the treatment of hepatitis B based on CRISPR/Cas9 technology. A hepatitis B therapy based on gene-editing technology has been developed in Russia, Sechenov University reported. “We have developed a new non-viral delivery system based on biodegradable nanoparticles. For the first time, we have learned how to package CRISPR/Cas…

Starting July 1, 2026, Government Resolution of the Russian Federation No. 1392 dated September 10, 2025, “On Amendments to Government Resolution of the Russian Federation No. 719 dated July 17, 2015,” will enter into force. The resolution introduces a points-based system for determining the country of origin of pharmaceutical products. To implement this resolution, the…

Over the past 20 years, the average cost of bringing a medicinal product to market has increased approximately threefold, reaching $2.5 billion, while the probability of success for an individual molecule at the late stages of clinical trials, according to Morgan Stanley estimates, has remained at just 8–12%. Against this backdrop, the traditional R&D model…

Despite sanctions and expectations of a complete withdrawal of foreign businesses, international pharmaceutical companies continue to hold key positions in the Russian medicines market. Based on the results of the first ten months of 2025, they account for more than 60% of sales in value terms and 36.9% in volume. International presence is especially pronounced…

The Ministry of Industry and Trade of Russia has prepared a draft government resolution proposing that, as of March 1, 2026, certain provisions of regulatory acts granting the ministry authority to confirm compliance of pharmaceutical manufacturers with Good Manufacturing Practice (GMP) requirements under national rules be declared invalid. This is another step toward formalizing the…